Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

1/6/25 8:30:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RXRX alert in real time by email

Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder and CEO Chris Gibson, PhD will present at the upcoming 43rd Annual JP Morgan Healthcare Conference in San Francisco.

On Monday, January 13, 7:30am PT (10:30am ET), at the Westin St. Francis in the Elizabethan Room A/B, Dr. Gibson will present updates on Recursion's latest clinical pipeline, partnerships, and platform following the company's recent combination with Exscientia. The talk will be available on Recursion's website for at least 30 days following the presentation here: https://ir.recursion.com/news-events/events-presentations.

Ryan Kelly
Recursion Pharmaceuticals
[email protected]

Get the next $RXRX alert in real time by email

Date	Price Target	Rating	Analyst
5/22/2023	$8.00	Equal-Weight	Morgan Stanley
3/16/2023	$17.00	Buy	Needham
9/16/2022	$20.00	Overweight	KeyBanc Capital Markets
4/18/2022	$10.00	Buy → Neutral	BofA Securities
3/4/2022	$32.00 → $10.00	Outperform → Market Perform	SVB Leerink
12/8/2021	$30.00 → $32.00	Outperform	SVB Leerink
9/21/2021	$37.00	Buy	Berenberg
8/16/2021	$33.00 → $30.00	Outperform	SVB Leerink

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$RXRX

$RXRX
Leadership Updates

Live Leadership Updates

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Altitude Lab Startups Raise $154M in Capital

Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

$RXRX
Financials

Live finance-specific insights

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

$RXRX
SEC Filings

Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 144 filed by Recursion Pharmaceuticals Inc.

SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.

$RXRX
Press Releases

Fastest customizable press release news feed in the world

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

$RXRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Taylor Ben R covered exercise/tax liability with 26,571 shares, decreasing direct ownership by 3% to 842,099 units (SEC Form 4)

Director Li Dean Y was granted 2,268 shares, increasing direct ownership by 3% to 79,618 units (SEC Form 4)

Director Dar Zavain was granted 2,745 shares, increasing direct ownership by 3% to 110,877 units (SEC Form 4)

$RXRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

$RXRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

Needham initiated coverage on Recursion Pharmaceuticals with a new price target

KeyBanc Capital Markets initiated coverage on Recursion Pharmaceuticals with a new price target

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $RXRX

$RXRX Leadership Updates

Live Leadership Updates

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Altitude Lab Startups Raise $154M in Capital

Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

$RXRX Financials

Live finance-specific insights

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

$RXRX SEC Filings

Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 144 filed by Recursion Pharmaceuticals Inc.

SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.

$RXRX Press Releases

Fastest customizable press release news feed in the world

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

$RXRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Taylor Ben R covered exercise/tax liability with 26,571 shares, decreasing direct ownership by 3% to 842,099 units (SEC Form 4)

Director Li Dean Y was granted 2,268 shares, increasing direct ownership by 3% to 79,618 units (SEC Form 4)

Director Dar Zavain was granted 2,745 shares, increasing direct ownership by 3% to 110,877 units (SEC Form 4)

$RXRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

$RXRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

Needham initiated coverage on Recursion Pharmaceuticals with a new price target

KeyBanc Capital Markets initiated coverage on Recursion Pharmaceuticals with a new price target

Recent Analyst Ratings for
$RXRX

$RXRX
Leadership Updates

$RXRX
Financials

$RXRX
SEC Filings

$RXRX
Press Releases

$RXRX
Insider Trading

$RXRX
Large Ownership Changes

$RXRX
Analyst Ratings